Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
IQVIA to Acquire Charles River Drug Discovery Assets to Expand R&D Pipeline
IQVIA Holdings agrees to acquire selected drug discovery assets from Charles River Laboratories to expand its end-to-end R&D and early-stage capabilities.
New Promising Drug PXS-5505 for Invasive Lobular Breast Cancer Tested
EPFL researchers have developed new preclinical models and successfully tested PXS-5505, a promising new drug targeting invasive lobular breast carcinoma.
EMA Backs Orphan Drug Status for Soligenix’s SGX945 in Behçet's Disease
Soligenix receives a positive EMA COMP opinion for SGX945 orphan drug designation to treat Behçet's Disease, advancing its novel dusquetide therapy.
Agentic AI & The Human Element: Building Trustworthy Clinical Trial Automation
Explore how agentic AI can automate and improve clinical trial setups while emphasizing the critical need for human oversight and strong governance protocols.
HotSpot Therapeutics to Present IRF5 Data at 15th European Lupus Meeting
HotSpot Therapeutics will present preclinical data from its IRF5 small molecule inhibitor program at the 15th European Lupus Meeting in Lisbon, Portugal.
FDA Accepts Beren Therapeutics' NDA for Niemann-Pick Disease Treatment
The FDA has accepted Beren Therapeutics' NDA for adrabetadex, a potential disease-modifying treatment for infantile-onset Niemann-Pick disease type C.
Gibson Oncology Starts Phase 2 Trial of LMP744 for Recurrent Glioblastoma
Gibson Oncology enters Phase 2 clinical trials with LMP744 to treat first-time recurrent glioblastoma, targeting topoisomerase 1 and cMYC oncogene inhibition.
Alembic Pharma Secures US FDA Approval for Generic Antifungal Topical
Alembic Pharmaceuticals receives final US FDA approval for its generic Efinaconazole Topical Solution, 10%, targeting the $500M onychomycosis market.
Preclinical Study: Hypoxia Therapy Controls Diabetes via Red Blood Cells
A new preclinical study in Cell Metabolism shows hypoxia therapy and red blood cells can regulate glucose levels, offering a potential diabetes treatment.
START Appoints Dr. Frank Smith as President of XenoSTART Preclinical Unit
The START Center for Cancer Research appoints Dr. Frank Smith as President of XenoSTART to scale preclinical operations and accelerate oncology R&D.
Gilead Acquires CAR-T Specialist Arcellx for $7.8B to Boost Cell Therapy
Gilead acquires CAR-T specialist Arcellx for $7.8bn to secure anito-cel, a BCMA-directed cell therapy for multiple myeloma currently under FDA review.
Preclinical vs Clinical Obesity: New Definitions to Reshape Diagnosis
Researchers evaluate a new definition splitting obesity into preclinical and clinical categories, finding 80% of affected individuals have clinical obesity.
2
3
4
5
6
7
8
9
10
